Curocell Inc. Logo

Curocell Inc.

Biotech developing enhanced CAR-T therapies for cancer using its OVIS™ platform.

372320 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
대전광역시 유성구 국제과학16로 11, 대전광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Curocell Inc. is a clinical-stage biotechnology company specializing in the research and development of Chimeric Antigen Receptor T-cell (CAR-T) therapies for cancer. A pioneer in South Korea, the company developed Limkato, the nation's first CAR-T therapy to complete clinical trials and be submitted for regulatory approval. Curocell's key innovation is its proprietary OVIS™ platform technology, which is engineered to enhance the efficacy and persistence of CAR-T cells by overcoming immune checkpoint-induced exhaustion. The company aims to address the limitations of existing immunotherapies and provide new treatment options for cancer patients, supported by its state-of-the-art GMP manufacturing facility.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Curocell Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-17 00:00
Share Issue/Capital Change
주요사항보고서(전환사채권발행결정)
Korean 75.9 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.6 MB
2025-08-08 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획변경승인신청) (CRC01(안발캅타젠오토류셀, 안발셀)의 B세포 급성 림프모구성 성인…
Korean 12.5 KB
2025-08-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-04 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 101.7 KB
2025-08-01 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청등결정) (CD19 CAR-T 치료제 CRC01의 전신 홍반성 루푸스 제1,2…
Korean 12.0 KB
2025-07-23 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB

Automate Your Workflow. Get a real-time feed of all Curocell Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Curocell Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
WAKAMOTO PHARMACEUTICAL CO.,LTD. Logo
Develops gastrointestinal and ophthalmic drugs for the health challenges of an aging society.
Japan 4512
WELLBIOTEC CO.,LTD Logo
Diversified in biopharma, EV chargers, and lithium supply for batteries.
South Korea 010600
WHANIN PHARM CO.,LTD Logo
Develops and sells pharmaceuticals, specializing in CNS, cardiovascular, and GI drugs.
South Korea 016580
WooGeneB&GCO.,Ltd Logo
Manufactures veterinary medicines, vaccines, and supplements for livestock and aquatic animals.
South Korea 018620
Xbrane Biopharma Logo
Develops affordable biosimilars for serious diseases using patented, high-yield production tech.
Sweden XBRANE
Xintela AB Logo
Develops stem cell therapies for osteoarthritis and venous leg ulcers using proprietary technology.
Sweden XINT
Xspray Pharma Logo
Develops improved cancer drugs (PKIs) using patented tech to circumvent secondary patents.
Sweden XSPRAY
Y.B Urban Renewal - Residential Development LTD Logo Israel CSURE-M
YUHAN CORPORATION Logo
A pharmaceutical & chemical firm developing drugs, supplements, consumer products, and APIs.
South Korea 000100
YUKI GOSEI KOGYO CO.,LTD. Logo
Manufactures fine chemicals, amino acids, and APIs via organic synthesis for global industries.
Japan 4531

Talk to a Data Expert

Have a question? We'll get back to you promptly.